Carpe Diem

Tag: Institutional Ownership

Kodiak Sciences KOD FunStock dashboard tracking institutional ownership, short interest, financials and Phase 3 biotech results.

Kodiak Sciences (KOD): Why the FunStock Gauges Keep Running After You Buy

Kodiak Sciences was around $26 when we published our cautiously bullish analysis after Baker Bros. made a major investment. Nine months later, KOD closed at $89.92 after successful Phase 3 results. But the bigger lesson may be what the FunStock gauges revealed along the way.

Read entire article

Tags: Baker Bros Advisors, Baker Brothers, biotech investing, biotech stocks, Carpe Diem, FDA approval, FunStock, FunStock Method, growth stocks, hedge funds, insider investing, institutional ownership, investment research, KOD, KOD stock, Kodiak Sciences, Kodiak Sciences stock, KSI-501, Phase 3 clinical trials, retinal disease, short interest, short squeeze, speculative investing, tabirafusp-ted, wet AMD, Zenkuda
Exploding spring transforming into a vertical stock chart with a car silhouette, symbolizing Avis (CAR) short squeeze driven by extreme short interest and insider buying, with chaotic market signals in the background

The Avis (CAR) Short Squeeze 2026: There Was a Clue 🚗📈

Avis (CAR) didn’t rally on fundamentals—it exploded on positioning. With 86% short interest and a massive insider buy, the clues were there. The lesson? Markets reward setups, not stories.

Read entire article

Tags: Avis stock, CAR stock, carpe diem, FUNanc1al, funanc1al investing, gamma squeeze, hedge funds, high short interest stocks, insider buying, institutional ownership, market psychology, meme stocks 2.0, short squeeze, stock analysis 2026, stock market anomalies, trading setups, volatility trading